Drug Profile
Carotuximab - Santen Pharmaceutical/TRACON Pharmaceuticals
Alternative Names: Chimeric Antibody TRC105; DE-122; NSC#754227; TRC-105Latest Information Update: 04 Nov 2019
Price :
$50
*
At a glance
- Originator Roswell Park Cancer Institute
- Developer National Cancer Institute (USA); Santen Pharmaceutical; TRACON Pharmaceuticals; University of Alabama at Birmingham; University of Minnesota
- Class Antifibrotics; Antineoplastics; Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Wet age-related macular degeneration
- Discontinued Acute myeloid leukaemia; Breast cancer; Choriocarcinoma; Colorectal cancer; Fallopian tube cancer; Glioblastoma; Haemangiosarcoma; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Precursor B-cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Renal cell carcinoma; Soft tissue sarcoma
Most Recent Events
- 31 Aug 2019 Tracon Pharmaceuticals completes a phase I/II trial for Liver cancer (Combination therapy) in USA (IV) (NCT02560779)
- 11 Aug 2019 Tracon Pharmaceuticals completes a phase I/II trial in Solid tumours in USA (IV) (NCT02354612)
- 08 Aug 2019 Santen completes enrolment in the AVANTE trial for Wet age-related macular degeneration in USA and Philippines